Skip to main
TBI
TBI logo

TrueBlue (TBI) Stock Forecast & Price Target

TrueBlue (TBI) Analyst Ratings

Based on 1 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TrueBlue Inc. reported a 2% year-over-year increase in revenues, primarily driven by strong performance in its commercial staffing segment, which experienced double-digit growth. The company's adjusted EBITDA margin improved by 50 basis points year-over-year to 0.7%, demonstrating effective management and strategic cost actions. Despite falling short of revenue growth guidance, the underlying fundamentals and strategic adjustments provide a solid foundation for future performance.

Bears say

TrueBlue Inc. reported a significant decline in its adjusted EBITDA margin, which fell 320 basis points year-over-year to 5.2%, primarily due to lower operating leverage amid a reduction in organic revenues. The PeopleReady segment, which generates the highest revenue for the company, experienced a 5% year-over-year decline in revenues, surpassing the previously guided decline of 3%, indicating ongoing weakness across various client verticals. Additionally, the company posted an adjusted loss per share of $(0.07), highlighting the challenges faced in maintaining profitability during this period of revenue contraction.

TrueBlue (TBI) has been analyzed by 1 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TrueBlue and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TrueBlue (TBI) Forecast

Analysts have given TrueBlue (TBI) a Buy based on their latest research and market trends.

According to 1 analysts, TrueBlue (TBI) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TrueBlue (TBI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.